Related Experiment Video
Updated: Sep 28, 2026

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
Published on: September 18, 2013
Antitumor effect of reduction of 150-kDa oxygen-regulated protein expression on human prostate cancer cells
Tohru Miyagi1, Osamu Hori, Kiyoshi Koshida
1Department of Urology, Kanazawa University School of Medicine, Kanazawa, Japan.
Background:
The 150-kDa oxygen-regulated protein ORP150, a new member of the heat shock protein family that functions as a molecular chaperone in the endoplasmic reticulum, was found to increase in infiltrating cancer cells. Since enhancement of ORP150 expression and the presence of vascular endothelial growth factor (VEGF) in human prostate cancer glands were immunohistochemically demonstrated, we examined whether transduced antisense ORP150 cDNA can reduce angiogenicity and tumorigenicity through suppression of VEGF secretion.
Methods:
Human prostate cancer specimens were immunohistochemically stained with fluorescein isothiocyanate (FITC) for ORP150 or vascular endothelial growth factor (VEGF). An adenovirus vector (Ad) carrying antisense ORP150 cDNA (AdCA-Antisense ORP150) was constructed and infected to prostate cancer DU145 cells. Expression of ORP150 in the cells was analyzed with western blotting and secretion of VEGF into the supernatant with an enzyme-linked immunoabsorbent assay (ELISA). Angiogenicity was evaluated by chorioallantoic membrane (CAM) assay. A nude mouse xenograft model was used to examine tumorigenicity.
Results:
Immunohistochemical study proved that the expression of ORP150 and VEGF was enhanced in the cytoplasm of prostate cancer cells. The Ad showed 100% transduction efficiency and minimum cytotoxicity when the cells were infected at a multiplicity of infection (MOI) of 20 for 24 h. Expression of ORP150 was substantially reduced by the antisense treatment. Secretion of VEGF into the culture supernatant was reduced to 30%. Consequently, the CAM assay showed relatively low angiogenicity, while marked suppression of tumor formation was observed in the xenograft model.
Conclusion:
Adenoviral-mediated antisense ORP150 cDNA transfer is well worth considering as an option for prostate cancer gene therapy.
Insights
Antisense ORP150 cDNA delivered via adenovirus reduced prostate cancer growth by suppressing VEGF secretion. This gene therapy approach shows promise for reducing tumor formation and angiogenicity.
Area of Science:
- Oncology
- Molecular Biology
- Gene Therapy
Background:
- Oxygen-regulated protein 150 (ORP150), a heat shock protein and molecular chaperone, is upregulated in infiltrating prostate cancer cells.
- Enhanced expression of ORP150 and vascular endothelial growth factor (VEGF) is observed in human prostate cancer.
- ORP150's role in promoting cancer progression warrants investigation for therapeutic targeting.
Purpose of the Study:
- To investigate if antisense ORP150 cDNA can suppress VEGF secretion, thereby reducing prostate cancer's angiogenicity and tumorigenicity.
- To evaluate the efficacy of adenoviral-mediated gene transfer of antisense ORP150 cDNA in prostate cancer models.
Main Methods:
- Immunohistochemical analysis of ORP150 and VEGF in prostate cancer specimens.
- Adenovirus vector carrying antisense ORP150 cDNA (AdCA-Antisense ORP150) for transduction of DU145 prostate cancer cells.
- Western blotting for ORP150 expression, ELISA for VEGF secretion, chorioallantoic membrane (CAM) assay for angiogenicity, and nude mouse xenograft model for tumorigenicity.
Main Results:
- Adenovirus vector demonstrated 100% transduction efficiency with minimal cytotoxicity.
- Antisense ORP150 cDNA significantly reduced ORP150 expression and suppressed VEGF secretion by 30%.
- Reduced angiogenicity in CAM assays and marked suppression of tumor formation in xenograft models were observed.
Conclusions:
- Adenoviral-mediated transfer of antisense ORP150 cDNA effectively inhibits prostate cancer growth and angiogenesis.
- This gene therapy strategy targeting ORP150 and VEGF suppression holds potential for prostate cancer treatment.
More Related Videos
07:48Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures
Published on: December 26, 2016
10:59Conditional Knockdown of Gene Expression in Cancer Cell Lines to Study the Recruitment of Monocytes/Macrophages to the Tumor Microenvironment
Published on: November 23, 2017
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...